ArticleInternational journal of clinical and experimental medicine2015
ING5 inhibits epithelial-mesenchymal transition in breast cancer by suppressing PI3K/Akt pathway.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- Defining the Tumor-Bone axis: the role of extracellular vesicles in a crucial exchange route for breast cancer development and progression.Clinical & experimental metastasis · 2025Review
- ING5: multifaceted roles beyond tumor suppression in cellular physiology and disease.Epigenetics & chromatin · 2025Review
- The Effect and Treatment of PIK3CA Mutations in Breast Cancer: Current Understanding and Future Directions.Medicina (Kaunas, Lithuania) · 2025Review
- Impact of microRNA variants on PI3K/AKT signaling in triple-negative breast cancer: comprehensive review.Medical oncology (Northwood, London, England) · 2024Review
- The roles of ING5 in cancer: A tumor suppressor.Frontiers in cell and developmental biology · 2022Review
- Transcriptional Regulation of ING5 and its Suppressive Effects on Gastric Cancer.Frontiers in oncology · 2022Article
- A Novel Splice Variant of the Inhibitor of Growth 3 Lacks the Plant Homeodomain and Regulates Epithelial-Mesenchymal Transition in Prostate Cancer Cells.Biomolecules · 2021Article
- LncRNA CASC2 inhibits hypoxia-induced pulmonary artery smooth muscle cell proliferation and migration by regulating the miR-222/ING5 axis.Cellular & molecular biology letters · 2020Article
- The Molecular Mechanism of Epithelial-Mesenchymal Transition for Breast Carcinogenesis.Biomolecules · 2019Review
- ING5 inhibits lung cancer invasion and epithelial-mesenchymal transition by inhibiting the WNT/β-catenin pathway.Thoracic cancer · 2019Article
- Upregulation of miR-376c-3p alleviates oxygen-glucose deprivation-induced cell injury by targeting ING5.Cellular & molecular biology letters · 2019Article
- Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association study.The Lancet. Respiratory medicine · 2019Article
- ING5-mediated antineuroblastoma effects of suberoylanilide hydroxamic acid.Cancer medicine · 2018Article
- Deregulation of MicroRNA-375 Inhibits Proliferation and Migration in Gastric Cancer in Association With Autophagy-Mediated AKT/mTOR Signaling Pathways.Technology in cancer research & treatment · 2018Article
- ING5 is a Potential Target for Osteosarcoma Therapy.Technology in cancer research & treatment · 2018Article
- The roles of ING5 expression in ovarian carcinogenesis and subsequent progression: a target of gene therapy.Oncotarget · 2017Article
- The nucleocytoplasmic translocation and up-regulation of ING5 protein in breast cancer: a potential target for gene therapy.Oncotarget · 2017Article
- The roles of ING5 in gliomas: a good marker for tumorigenesis and a potential target for gene therapy.Oncotarget · 2017Article
- ING5 knockdown enhances migration and invasion of lung cancer cells by inducing EMT via EGFR/PI3K/Akt and IL-6/STAT3 signaling pathways.Oncotarget · 2017Article
- ING5 suppresses breast cancer progression and is regulated by miR-24.Molecular cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial-mesenchymal transition (EMT) is a crucial step in tumor progression and has an important role during cancer invasion and metastasis. The proteins of the inhibitor of growth (ING) candidate tumor suppressor family are involved in multiple cellular functions such as cell cycle regulation and apoptosis. ING5 is a member of the family. However, the role of ING5 in breast cancer is still unclear. Thus, the aim of this study is to explore the role of ING5 in breast cancer. In the present study, we showed that ING5 is involved in the pathogenesis of breast cancer. ING5 is down-regulated in breast cancer tissues and cell lines. Overexpression of ING5 significantly inhibited breast cancer cell migration, invasion, and EMT phenotype, moreover, overexpression of ING5 significantly the phosphorylation of PI3K and Aktin in breast cancer cells. In conclusion, our findings show that ING5 can efficiently inhibit the EMT progression in breast cancer cells by suppressing PI3K/Akt signaling pathway. Therefore, ING5 may be a good molecular target for the prevention and treatment of breast cancer.
Indexed as
Identifiers
26629040PMC4658929W2194676170What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.